Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: CALGB C90203: Randomized phase III study of neo-adjuvant Docetaxel and Androgen deprivation prior to radical prostatectomy vs immediate radical prostatectomy in patients with high risk clinically localized prostate cancer.

 


CALGB C90203: Randomized phase III study of neo-adjuvant Docetaxel and Androgen deprivation prior to radical prostatectomy vs immediate radical prostatectomy in patients with high risk clinically localized prostate cancer.


Trial Focus

Prostate Cancer

Objective

         This research is being done in men with prostate cancer who are at significant risk of having the cancer come back if they are treated with surgery alone. We are trying to determine if giving chemotherapy with hormone therapy before surgery reduces the r

IRB Protocol #

07-0182

Trial Status

OPEN

Principle Investigator

PAUL MARONI

Sponsor

CALGB

Contact

MARY ANDUHA at (720)848-0659 or MARY.ANDUHA@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center University of Colorado Hospital Valley View Hospital Dept Of Veterans Affairs Medical Center University of Colorado Hospital Valley View Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The treatment period will last approximately six months. A follow-up period will consist of physician contact. // Eligibility criteria include but are not limited to 18 years or older with prostate cancer and at risk of cancer recurrence after surgery to remove the prostate.Eligibility criteria include but are not limited to 18 years or older with prostate cancer and at risk of cancer recurrence after surgery to remove the prostate.